Relay Therapeutics integrates unprecedented computational power with experimental approaches across structural biology, biophysics, chemistry and biology to illuminate protein mobility and design therapies. Its platform aims to modulate protein conformation to create novel therapeutics, with initial programs focused on oncology. Early discovery efforts have produced highly selective inhibitors targeting disease-causing proteins in genomically defined patient populations. The company plans to expand its discovery efforts, advance existing programs into the clinic, and bolster its platform and team using proceeds from the financing. Relay is headquartered in Cambridge, Massachusetts and was launched in 2016 with initial financing from Third Rock Ventures and an affiliate of D. E. Shaw Research. Prior to the Series C it had raised $120 million. Relay Therapeutics builds a drug-discovery platform that illuminates protein motion by combining structural biology, biophysics, computation, chemistry and biology. The company applies this platform to discover and develop a pipeline of protein motion–based therapies, with initial programs focused on oncology. Relay intends to advance its oncology candidates toward clinical trials and to deepen integration of its experimental and computational technologies. The company is privately held, headquartered in Cambridge, Massachusetts, and was launched in 2016 with financing from Third Rock Ventures and an affiliate of D. E. Shaw Research. Sanjiv Patel, MD, serves as President and Chief Executive Officer and has emphasized advancing the integrated platform and pipeline toward transformative targeted therapies for patients. Relay Therapeutics is developing an integrated drug discovery engine that centers on protein motion, applying structural biology, biophysics, computation, chemistry and biology to illuminate dynamic protein behavior. The platform aims to move drug discovery from static structural snapshots to dynamic ‘‘movies’’ of molecular machines, enabling design of medicines against targets previously challenging or inaccessible. The company’s initial programs are focused on oncology and on translating insights about protein motion into novel therapeutics. Relay was launched in 2016 and is headquartered in Cambridge, Massachusetts. Its founding team includes experts in structural biology, biophysics and biomolecular simulation, among them Matthew Jacobson, Dorothee Kern, Mark Murcko and D. E. Shaw Research representation. Financially, Relay began operations with $57 million in Series A financing to build its discovery pipeline.

Total raised

$520M

Funding rounds

3

Latest round

Series C

Latest activity

Dec 2018